The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Hansson, OskarLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital (författare)

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Neurovetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Neurosciences hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng
Alzheimer's disease
appropriate use recommendations
blood-based
biomarkers
diagnosis
prognosis
plasma neurofilament light
fibrillary acidic protein
phosphorylated
tau 181
amyloid-beta
clinical-diagnosis
dementia
accuracy
performance
prevalence
validation
Neurosciences & Neurology
blood-based biomarkers

Edelmayer, R. M.Alzheimer's Association: Alzheimer's Disease and Dementia (författare)
Boxer, A. L.University of California, San Francisco (författare)
Carrillo, M. C.Alzheimer's Association: Alzheimer's Disease and Dementia (författare)
Mielke, M. M.Wake Forest University (författare)
Rabinovici, G. D.University of California, San Francisco (författare)
Salloway, S.Brown University (författare)
Sperling, R.Harvard Medical School (författare)
Zetterberg, Henrik,1973Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,University College London,Sahlgrenska University Hospital,Sahlgrenska Academy(Swepub:lu)med-hiz (författare)
Teunissen, C. E.Academic Medical Center of University of Amsterdam (AMC) (författare)
Klinisk minnesforskningForskargrupper vid Lunds universitet (creator_code:org_t)

Av författaren/redakt...: Hansson, Oskar; Edelmayer, R. M.; Boxer, A. L.; Carrillo, M. C.; Mielke, M. M.; Rabinovici, G. D ...; visa fler...; Salloway, S.; Sperling, R.; Zetterberg, Henr ...; Teunissen, C. E.; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Neurovetenskaper

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.